Evidence Suggests a Possible Decline in US Obesity Rates Amid Rising Use of GLP-1 Drugs
The United States has faced an obesity epidemic since the late 1970s, but recent evidence suggests that the trend of rising obesity rates may be reversing. Benjamin Rader, an epidemiologist at Boston Children's Hospital and Harvard Medical School, indicates that there are signs of a turning point. A study published in 2024, analyzing data from over 16 million adults, found a decline in obesity prevalence for the first time in more than a decade. Additionally, the National Health and Nutrition Examination Survey reported a slight decrease in obesity rates between 2021 and 2023, supported by recent survey data.
This potential decline coincides with the growing use of GLP-1 agonist medications, such as Ozempic, Wegovy, and Zepbound, which have seen prescriptions quadruple from 2021 to early 2026. Originally developed to treat Type 2 diabetes, these medications mimic an intestinal hormone that promotes feelings of fullness and slows gastric emptying, leading to significant weight loss for many users.
Rader believes that the impact of these medications is likely reflected in the data, stating that he is moderately confident they are contributing to the observed decline in obesity rates. Peminda Cabandugama, an endocrinologist and spokesperson for The Obesity Society, concurs, noting strong evidence of a significant decline in obesity prevalence linked to the increased use of GLP-1 medications and heightened awareness of weight management.
However, Rader emphasizes that definitive proof of a causal relationship remains elusive. While the drugs have proven effective for many individuals, he cautions that it is premature to conclude whether this trend will lead to a sustained decrease in obesity rates over the next two decades. Cabandugama also highlights the potential influence of lifestyle changes during and after the COVID-19 pandemic, suggesting that the observed trends may stem from a combination of factors, including increased medication use and a growing emphasis on weight management.
Some researchers remain skeptical about the permanence of this decline. A study from the Institute of Health Metrics and Evaluation (IHME) at the University of Washington forecasts an increase in obesity rates through 2035, predicting that the percentage of obese adults could rise from 42.5% in 2022 to 46.9% by 2035. While Rader acknowledges the validity of these predictions, he notes that many models predate the surge in GLP-1 drug usage and may not account for their potential impact.
The IHME study authors recognize this critique but point out that only a small fraction of obese individuals currently utilize these medications, and many discontinue treatment within a year, with some regaining weight after initial losses. They stress the need for more comprehensive data to determine the long-term effects of these drugs on obesity rates.
Cabandugama urges caution, reiterating that while current indicators suggest a decline, it is still too early to determine if this represents a genuine trend reversal. The understanding of obesity has evolved, recognizing it as a complex chronic condition influenced by biological, genetic, social, and psychological factors.
If the US is indeed at a turning point, the implications could be profound. Weight loss among obese individuals not only reduces the risk of associated health issues but also enhances mobility, independence, and overall quality of life. Cabandugama notes that improvements in cardiometabolic health indicators, such as blood glucose levels and cardiovascular health, could alleviate pressure on the healthcare system in the long run.
Despite the hopeful signs, Rader underscores that obesity remains a significant public health crisis in America, necessitating ongoing attention, funding, and diverse solutions, particularly given that GLP-1 medications are not accessible to all due to cost and other barriers. He warns that a turning point does not imply that the issue is resolved or that vigilance is no longer required.




